



NIH AIDS Reagent Program

20301 Century Boulevard
Building 6, Suite 200
Germantown, MD 20874
USA

Phone: 240 686 4740
Fax: 301 515 4015
aidsreagent.org

DATA SHEET

Reagent:	☒ FIV AZR-1 Infected CRFK Cells
Catalog Number:	1446
Lot Number:	098104
Release Category:	A
Provided:	3.8 x 10 ⁶ cells/mL. Viability, 96%.
Cell Type:	Crandall feline kidney cells. Epithelial-like, adherent cell line. Little syncytia formation is seen.
Propagation Medium:	A 1:1 mixture of Liebovitz (L-15) medium and DMEM supplemented with L-glutamine and pen-strep, 10% fetal bovine serum, and 10 µM AZT.
Freeze Medium:	Culture medium, 90%; DMSO, 10%. Should be frozen with AZT.
Growth Characteristics:	Doubling time is 16-24 hours. Split when the culture becomes confluent. Medium should be changed at least twice weekly, but preferably every other day. High titers of virus can be obtained by collecting and replacing the culture medium from nearly confluent cells. These cells are very hardy and can be maintained in culture for long periods of time.
Sterility:	Negative for bacteria, fungi, and mycoplasma.
Description:	CRFK cells infected with FIV AZR-1
Special Characteristics:	Resistance was selected for entirely <i>in vitro</i> . Resistance is lost rapidly in the absence of AZT. The infected cells produce virus continually. The virus also replicates in feline lymphocytes and lymphoid cell lines.
Recommended Storage:	Liquid nitrogen.

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

Contributor: Dr. Thomas North.

References: Remington KM, Chesebro B, Wehrly K, Pedersen NC, North TW. Mutants of feline immunodeficiency virus resistant to 3'Azido-3'-deoxythymidine. *J Virol* **65**:308-312, 1991.

NOTE: Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: FIV AZR-1 Infected CRFK Cells from Dr. Thomas North." Please include the reference cited above in any publications.

Last Updated July 02, 2018

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.